CLOZAPINE TABLETS
Država: Kanada
Jezik: engleski
Izvor: Health Canada
Svojstava lijeka
(SPC)
11-10-2018
Neki dokumenti za ovaj proizvod trenutno nisu dostupni, možete poslati zahtjev u našu korisničku službu i mi ćemo vas obavijestiti čim ih budemo mogli dobiti.
Pošalji zahtjev.
Pošalji zahtjev.
Aktivni sastojci:
CLOZAPINE
Dostupno od:
INNOMAR STRATEGIES INC.
ATC koda:
N05AH02
INN (International ime):
CLOZAPINE
Doziranje:
25MG
Farmaceutski oblik:
TABLET
Sastav:
CLOZAPINE 25MG
Administracija rute:
ORAL
Jedinice u paketu:
100
Tip recepta:
Prescription
Područje terapije:
ATYPICAL ANTIPSYCHOTICS
Proizvod sažetak:
Active ingredient group (AIG) number: 0122583001; AHFS:
Status autorizacije:
APPROVED
Datum autorizacije:
2018-10-11
Svojstava lijeka
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
Clozapine Tablets
25 mg and 100 mg
House Standard
Antipsychotic Agent
Innomar Strategies Inc. DATE OF REVISION:
3470 Superior Court October 11, 2018
Oakville, Ontario
L6L 0C4
Control No.: 219938
_Product Monograph _
_August 2018 _
_Page 2 of 57_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
.........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
..................................................................................................
5
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
...............................................................................................
21
DRUG INTERACTIONS
................................................................................................
28
DOSAGE AND ADMINISTRATION
...............................................................................
29
OVERDOSAGE
............................................................................................................
33
ACTION AND CLINICAL PHARMACOLOGY
................................................................ 35
STORAGE AND STABILITY
.........................................................................................
36
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 36
PART II: SCIENTIFIC INFORMATION
....................................................................................
38
PHARMACEUTICAL INFORMATION
...........................................................................
38
CLINICAL TRIALS
........................................................................................................
39
DETAILED PHARMACOLOGY
...........................
Pročitajte cijeli dokument
